Please login to the form below

Not currently logged in
Email:
Password:

Investigation into Merck & Co drug

The US Food and Drugs Administration announced on March 27 that it has launched an investigation into the drug Singulair, which is manufactured by Merck & Co.

The US Food and Drugs Administration (FDA) announced on March 27 that it has launched an investigation into the drug Singulair, which is manufactured by Merck & Co.

The FDA has said that is investigation a possible association between the use of the drug and suicidal behaviour and thinking after analysing the most up-to-date information pertaining to the use of Singulair.

Singulair is a leukotriene receptor antagonist indicated for the treatment of patients with asthma and symptoms of allergic rhinitis and to prevent exercise-induced asthma.

The FDA said: "Until further information is available, healthcare professionals and caregivers should monitor patients taking Singulair for suicidality (suicidal thinking and behaviour) and changes in behaviour and mood."

The FDA did, however, caution that "patients should not stop taking Singulair before talking to their doctor if they have questions about this new information."

Evaluation of the date and the possible link between Singulair and suicidal behaviour and thinking may take up to nine months at which point the FDA's findings will be made available to the public.

27th March 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Anthill Agency

Digital communications agency empowering clients through their digital transformation journey. Whether through training, delivering solutions or devising digital strategies, we...

Latest intelligence

segmentation_pie_thumb.jpg
If you’re not thinking segmentation, you’re not thinking
Having a background in market research I’ve been lucky to work on a number of customer segmentations in my time but working in creative communications it is still too rare...
Improving Outcomes in the Treatment of Opioid Dependence Highlights Report
The 16th annual ‘Improving Outcomes in the Treatment of Opioid Dependence’ (IOTOD)conference took place at the Hilton Madrid Airport hotel on 15–16 May 2018....
Londonvelophobia (fear of cycling in London) – debunked
...

Infographics